News & Updates
Filter by Specialty:

Vilobelimab augments treatment armamentarium for critically ill COVID-19 patients
In the phase III part of the PANAMO trial, the anti-C5a monoclonal antibody vilobelimab, when added to standard of care (SoC), improved survival in COVID-19 patients who required invasive mechanical ventilation (IMV).
Vilobelimab augments treatment armamentarium for critically ill COVID-19 patients
29 Nov 2022
Breath-holding may predict adverse outcomes in COVID-19 patients
A higher prediction score in breath-holding is associated with nearly a fivefold increased likelihood of respiratory failure in COVID-19 patients, as well as with greater severity of pulmonary deficits seen in chest imaging, a study has shown.
Breath-holding may predict adverse outcomes in COVID-19 patients
28 Nov 2022
Extended-release morphine of no benefit to COPD patients with breathlessness
A week-long treatment course of low-dose, extended-release morphine does not appear to be effective at relieving breathlessness in patients with chronic obstructive pulmonary disease (COPD), according to a study.
Extended-release morphine of no benefit to COPD patients with breathlessness
25 Nov 2022
Some COVID-19 patients see persistent lung disease 6 months after infection
Radiographic and physiologic signs of lung disease persist for up to 6 months after infection from COVID-19, reports a recent study.
Some COVID-19 patients see persistent lung disease 6 months after infection
24 Nov 2022
GLP-1 receptor agonists halt COPD exacerbations in T2D patients
Use of glucagon-like peptide 1 (GLP-1) receptor agonists or sodium-glucose co-transporter-2 (SGLT-2) inhibitors, compared with sulfonylureas, helps prevent severe exacerbations of chronic obstructive pulmonary disease (COPD) in patients with type 2 diabetes (T2D), a UK study has shown.